Numbers

The Numbers

Centene trades at $53.69 on $195B of revenue — a $26B market cap for the second-largest US health insurer. The stock is priced for permanent margin impairment after the FY2025 goodwill write-down, but normalized earnings are recovering faster than the market expects. The single metric most likely to rerate this stock is the Medicaid HBR — if Q1 FY2026's 93.1% trajectory holds through the year, adjusted EPS of $6+ is achievable by FY2027, implying the stock trades at under 9x normalized earnings.

Revenue & Earnings Power — 20-Year View

Centene has never had a year of revenue decline. From $1.2B in FY2005 to $195B in FY2025 — a 30% CAGR driven by organic Medicaid wins and transformative M&A (Health Net 2016, Fidelis 2018, WellCare 2020).

The FY2025 operating loss of -$7.6B is entirely the $6.7B goodwill impairment plus $513M Magellan impairment. Adjusted operating income was approximately $1.0B — depressed but positive.

Pre-impairment operating margins averaged 2.0% over FY2016-2024. The managed care business operates on razor-thin margins by design — the profit is in the scale.

Quarterly Revenue Momentum

Revenue growth accelerated from 6% in FY2024 to 19% in FY2025, driven by PDP premium yield (IRA-driven shift in cost-sharing), Marketplace membership growth (+26% YoY), and Medicaid rate increases. Q1 FY2026 revenue of $49.9B continues the trend.

Cash Generation — Are the Earnings Real?

FY2024's operating cash flow of $154M was an aberration — $4.3B of receivables growth (mostly Marketplace risk adjustment timing) drained working capital. FY2025's $5.1B normalized the picture. Over FY2020-2025, cumulative operating cash flow totaled $29.3B against cumulative net income of $3.9B — demonstrating that even in the loss year, the business throws off real cash.

Capex runs at under 0.5% of revenue ($767M on $195B) — this is an asset-light business. FCF of $4.3B in FY2025 represents a 16% FCF yield on the current $26.4B market cap.

Capital Allocation

Centene has never paid a dividend. Capital allocation shifted dramatically post-WellCare: FY2022-2024 saw $7.9B in buybacks (shares fell from 582M to 492M), reducing diluted share count by 15%. FY2025 buybacks slowed to $475M, and 2026 guidance includes zero buybacks — cash is being redirected to debt reduction and margin recovery investments.

SBC runs at $204M (FY2025), or about 0.1% of revenue — immaterial dilution.

Balance Sheet Health

Total long-term debt of $17.4B against equity of $20.0B (debt-to-capital 46.5% at year-end, improved to 43.2% by Q1 FY2026). The equity decline from FY2024's $26.4B to FY2025's $20.0B is entirely the goodwill impairment write-through. The balance sheet is strained but manageable — interest expense of $678M is well-covered by $5.1B operating cash flow (7.5x coverage).

Goodwill fell from $17.6B to $10.8B after the impairment. Remaining goodwill of $10.8B against $20.0B equity means intangible-adjusted book value is thin, but for a managed care company with no hard assets, this is typical.

Valuation — Historical Context

On FY2025 adjusted EPS of $2.08, the stock trades at 25.8x — expensive on trough earnings. On the raised FY2026 guidance of over $3.40, forward P/E is ~15.8x. If EPS normalizes toward $6+ by FY2027 (pre-impairment FY2024 level was $7.17), the stock is under 9x forward.

The 10-year median adjusted P/E is approximately 18x. At 18x on $6 normalized EPS = $108. At 15x (Medicaid peer discount) = $90. At 10x (distressed pricing) = $60, roughly where it trades today.

Peer Comparison

Centene's 16.3% FCF yield dwarfs every peer. Price-to-revenue of 0.14x is the lowest in the group by a wide margin — the market assigns almost no value to $195B of revenue. This reflects the depressed-earnings narrative, but if margins normalize, the rerating potential is substantial.

Fair Value & Scenario

Bear ($34): Medicaid margins don't recover, Marketplace shrinks further, medical cost trends persist. Market applies distressed 10x on guided $3.40 EPS.

Base ($82): HBR normalizes to ~89% by FY2027, Medicaid rates catch up, Marketplace repricing holds. 15x on $5.50 normalized EPS — peer-median multiple on recovered earnings.

Bull ($126): Full margin recovery to FY2024 levels ($7 EPS), D-SNP growth accelerates, market re-rates to historical 18x.

The numbers confirm that Centene is a massive business generating substantial cash flow through a period of temporary margin compression. The FY2025 goodwill impairment is backward-looking noise. What the popular narrative misses is the speed of margin recovery visible in Q1 FY2026 — and the possibility that the market is pricing permanent damage to a cyclical problem. Watch Q2 FY2026 Medicaid HBR and Marketplace membership retention to determine whether the base case holds or the bear case materializes.